Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Horvath, A; Habisch, H; Prietl, B; Pfeifer, V; Balazs, I; Kovacs, G; Foris, V; John, N; Kleinschek, D; Feldbacher, N; Grønbæk, H; Møller, HJ; Žukauskaitė, K; Madl, T; Stadlbauer, V.
Alteration of the Gut-Lung Axis After Severe COVID-19 Infection and Modulation Through Probiotics: A Randomized, Controlled Pilot Study.
Nutrients. 2024; 16(22):
Doi: 10.3390/nu16223840
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Horvath Angela
- Stadlbauer-Köllner Vanessa
- Co-Autor*innen der Med Uni Graz
- Balazs Irina
- Feldbacher Nicole
- Foris Vasile
- Habisch Hansjörg
- John Nikolaus
- Kovacs Gabor
- Madl Tobias
- Pfeifer Verena
- Prietl Barbara
- Zukauskaite Kristina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The gut-lung axis could be a potential therapeutic target for improving post-acute COVID-19 symptoms, and probiotics have been proposed as possible modulators. AIM: We conducted a pilot study to understand alterations in the gut-lung axis and to explore the effects of a probiotic in post-acute COVID-19 disease. METHODS: We included patients after severe COVID-19 disease (sCOV, n = 21) in a randomized, placebo-controlled trial to test the effect of a probiotic (Pro-Vi 5, Institute Allergosan, Graz, Austria) in a six-month intervention and used patients after mild disease (mCOV, n = 10) as controls, to compare the intestinal microbiome, metabolome, and patient-reported outcomes and biomarkers along the gut-lung axis at baseline and throughout probiotic intervention. RESULTS: Compared to mCOV patients, sCOV patients showed lower microbial richness, which was significantly improved by probiotic intervention. A reorganization of Ruminococcaceae and Lachnospiraceae taxa was observed in sCOV patients but remained unaffected by the intervention. Serum metabolome showed a dysregulation of lipoproteins in accordance with higher BMI and comorbidities in sCOV patients. HDL and LDL fractions/components were temporarily decreased in the probiotic group. Stool metabolome was altered at baseline in sCOV patients and an increase in L-DOPA after 3 months and butyrate after 6 months of intervention could be observed. Probiotics partially improved reduced quality of life and modulated altered immune responses in sCOV patients. Increased intestinal permeability at baseline remained unaffected. CONCLUSION: The study provides evidence of long-term alterations of the gut-lung axis after severe COVID-19 infection and suggests that probiotics can modulate the biomarkers of the gut-lung axis.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Probiotics - therapeutic use, administration & dosage
- Pilot Projects - administration & dosage
- COVID-19 - therapy
- Gastrointestinal Microbiome - administration & dosage
- Male - administration & dosage
- Female - administration & dosage
- Middle Aged - administration & dosage
- Lung - administration & dosage
- SARS-CoV-2 - administration & dosage
- Aged - administration & dosage
- Metabolome - administration & dosage
- Adult - administration & dosage
- Feces - microbiology
- Biomarkers - blood
- Severity of Illness Index - administration & dosage
- Find related publications in this database (Keywords)
- COVID-19
- probiotics
- gut microbiome
- gut-lung axis
- immune phenotyping
- neutrophil function
- quality of life